Company tackling antimicrobial resistance appoint former Bayer VP as new managing director
British company Matoke Pharma have appointed former Bayer VP, Alan Westwood, as the firm’s new managing director, a role in which he will lead the development of Matoke’s Reactive Oxygen technology.
Having spent 35 years at German pharma giant Bayer, Westwood took on roles of increasing seniority before becoming the company’s Vice President of Global Strategic Marketing for anti-infectives.
Bringing to the role his expertise in the area of anti-infectives, Westwood’s new position as managing director will have him oversee the development of the company’s lead candidate RO101, a novel antimicrobial based in the company’s Reactive Oxygen technology. Matoke hopes to take RO101 into phase I clinical trials in the coming year.
Westwood commented: “I’m delighted to take up the role of Managing Director of Matoke Pharma at this exciting time as it moves closer to achieving its ambition to bring a breakthrough antimicrobial medicinal product to market. Reactive Oxygen’s range of potential applications make it more than a conventional antibiotic – it is one of the most promising innovations under development. I look forward to taking it to the next stage of clinical development to ensure patients benefit from this innovation.”
The novel antimicrobial, which holds potential as a primary treatment for chronic non-healing wounds, may be vital in the fight against antimicrobial resistance (AMR). The company itself was founded by former Halfords managing director Ian Staples in 2010, with the intention of developing new antimicrobial drugs to assist in the battle against AMR.
Commenting on Westwood’s appointment, Ian Staples, Chief Executive Matoke Pharma’s parent company, Matoke Holdings Ltd, said: “Alan’s appointment is a great step forward for Matoke and his arrival is testament to the promise that Reactive Oxygen has shown to create breakthrough medicinal products. New antimicrobial treatments are desperately needed to halt the rise of antimicrobial resistance, which is forecast to contribute to 10 million deaths worldwide by 2050. Matoke now has a highly experienced R&D team to take RO101 forward to Phase I clinical trials in 2019 and take on this global threat.”